Home » Newsletters » BioWorld Science

BioWorld Science

July 7, 2020

View Archived Issues

New aryl formyl piperidine derivatives reversibly inhibiting MAGL for the treatment of depression

ASO approach fixes myelin

FMF is Mediterranean's SCD

GB-1874, a novel inhibitor of Wnt signaling with activity in models of CRC

Amgen presents first orally available Mcl-1 inhibitor, AMG-397

OncoSec Medical divulges expression vectors encoding nucleic acid sequences for cancer

SIAT patents anti-H7N9 fully human monoclonal antibody 2G3 for H7N9 viral infection

Japanese researchers report new immunosuppressants

Sunshine Lake Pharma presents CD19-targeting antibodies

AdAlta moves AD-214 into the clinic

Researchers identify claudin 18.2-targeting antibodies

FDA lifts partial clinical hold on pivotal phase II study of camidanlumab tesirine

Clinical study of desidustat for the management of COVID-19 approved in Mexico

EXOSC4 gene is tied to breast cancer progression and poor survival

Suzhou Kintor Pharmaceuticals studies lead c-Myc/MAX protein-protein interaction inhibitor

Results from phase II RELIEF study of BLU-5937 in refractory chronic cough

Phase III ASCENT study of Trodelvy meets primary and key secondary endpoints

First participant enrolled in phase I study of ANAVEX 3-71

GI goblet cells prevent GvHD after stem cell transplant

CSL Behring initiates phase II study of CSL-312 for respiratory distress in patients with COVID-19

FDA places clinical hold on MELANI-01 study

Dimerix advances understanding of DMX-700 in COPD

ADGRG1 promotes TNBC progression and is a therapeutic druggable target

Otonomy reports treatment response in phase I/II trial of OTO-313 for tinnitus

Cabaletta opens enrollment in phase I study of DSG3-CAART in mucosal-dominant pemphigus vulgaris

European Commission approves Enerzair Breezhaler for uncontrolled asthma

Immune Regulation and DynPort partner to advance IRL-201104 for COVID-19-related ARDS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.